Summit Therapeutics Inc
NASDAQ:SMMT
Summit Therapeutics Inc
Cash from Operating Activities
Summit Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Summit Therapeutics Inc
NASDAQ:SMMT
|
Cash from Operating Activities
-$142.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$19.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$9.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$12B
|
CAGR 3-Years
9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$5.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Summit Therapeutics Inc
Glance View
Summit Therapeutics Inc., headquartered in Cambridge, Massachusetts, has carved a niche in the biopharmaceutical landscape with its focus on addressing serious unmet medical needs, primarily through the development of innovative antibiotics and therapies. The company gained significant attention with its efforts to combat antibiotic resistance, a global health threat. Their flagship endeavor, Ridinilazole, is an antibiotic designed to treat C. difficile infections, a prevalent and often severe bacterial infection affecting the gut. The company's proposition is simple yet impactful: develop effective treatments that not only address infections but also potentially reduce recurrence, thereby offering a better therapeutic alternative to existing solutions. Summit's business model is built around advancing their drug pipeline through rigorous clinical trials, securing regulatory approvals, and ultimately achieving commercialization either independently or through strategic partnerships. The partnerships are critical, as they allow Summit to leverage the expertise and market reach of larger pharmaceutical companies. Additionally, these alliances provide financial backing, helping offset the costly nature of drug development. Revenue is primarily driven from these collaborations through milestone payments and eventual product royalties, once their therapies hit the market. This strategic approach allows Summit to focus its resources on research and development while aligning with partners to navigate the complexities of bringing new therapies to patients globally.
See Also
What is Summit Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-142.1m
USD
Based on the financial report for Dec 31, 2024, Summit Therapeutics Inc's Cash from Operating Activities amounts to -142.1m USD.
What is Summit Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-47%
Over the last year, the Cash from Operating Activities growth was -85%. The average annual Cash from Operating Activities growth rates for Summit Therapeutics Inc have been -25% over the past three years , -47% over the past five years .